Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Gastric/GEJ Cancer: Immunotherapeutic Strategies

June 26th 2018

Targeting VEGF in Gastric/GEJ Cancer Treatment

June 26th 2018

Understanding HER2's Role in Gastric/GEJ Cancer

June 26th 2018

Optimizing Treatment of Metastatic Gastric/GEJ Cancer

June 26th 2018

Postoperative Approaches to Treating Gastric/GEJ Cancer

June 26th 2018

Optimal Perioperative Chemotherapy in Gastric/GEJ Cancer

June 26th 2018

Perioperative Therapy in Gastric/GEJ Cancer

June 26th 2018

Gastric/GEJ Cancers: Challenges in Multimodality Care

June 26th 2018

Multidisciplinary Management of Gastric/GEJ Cancers

June 26th 2018

Molecular Testing in Metastatic Gastric/GEJ Cancer

June 26th 2018

Optimal Stratification of Gastroesophageal Cancers

June 26th 2018

Dr. Kopetz on the Importance of Molecular Testing in CRC

June 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.

O'Neil Shares Insight on Growing Therapeutic Arsenal for GI Tract NETs

June 25th 2018

Bert H. O’Neil, MD, discusses the prevalence of neuroendocrine tumors and the agents that are used to treat patients who present with them.

Regorafenib Dose-Escalation Superior to Standard Dosing in mCRC

June 22nd 2018

Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.

TAS-102 Benefit Consistent in Real-World Study for mCRC

June 22nd 2018

TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.

O'Reilly Discusses Status of Immunotherapy Research in Pancreas Cancer

June 22nd 2018

Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.

Dr. O'Reilly on Immunotherapy in Pancreatic Cancer

June 22nd 2018

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

Dr. Finn Recaps Second-Line Advancements in HCC

June 22nd 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, recaps recent second-line advancements in hepatocellular carcinoma.

Atezolizumab Combo Not Superior to Regorafenib for mCRC

June 22nd 2018

Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer.

TAS-102 Prolongs Survival in Phase III Gastric Cancer Study

June 21st 2018

TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death compared with placebo in patients with heavily pretreated metastatic or advanced gastric cancer.